Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ44708

The effect of COQ2 gene polymorphism (C>A) (rs6818847) on the occurrence of myopathy in statin-treated patients

Hala Y. Kadhom, Mazin H. Ouda


Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) can cause skeletal muscle toxicity; the risk of toxicity is elevated by drug interactions and pharmacogenetic factors that increase the concentration of statins in plasma. The aims of this study were to detect the genetic polymorphism of COQ2 gene particularly COQ2 (C>A) (rs6818847) that involved in biosynthesis of CoQ10 enzyme in Iraqi patients treated with 40mg atorvastatin. The study comprised 150 hyperlipidemic patients taking 40 mg atorvastatin once a day, in whom CoQ10, CK, lipid profile, TSH and renal function test were all evaluated. The Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS PCR) was used in this study to identify COQ2 (C>A) (rs6818847). Results finding in this study that, COQ2 (C>A) (rs6818847), has been found to have several genotypes, all of which have been found in statin-taking research participants. The current investigation revealed a significant (p<0.05) connection between the studied SNP of COQ2 gene and serum CoQ10 level. Although the value did not rise to the extent that qualifies to be statistically significant, however, patients who have these genotypes are more sensitive to statin therapy, because the statin itself increase creatine kinase level by causing muscle damage and release this enzyme so, it exacerbated the condition. In conclusion, there is a significant impact of polymorphism (rs6818847) within the COQ2 gene in Iraqi dyslipidemic individuals treated with high doses of atorvastatin; this poses a danger of developing myopathy connected with the use of atorvastatin.


Myopathy, Statin, COQ2 gene, CoQ10.

Full Text